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Abstract
Sickle cell anemia (SCA) is the commonest severe monogenic disorders of humans. The disease has
been highly characterized in high-income countries but not in sub-Saharan Africa where SCA is
most prevalent. We conducted a retrospective cohort study of all children 0–13 years admitted
from within a defined study area to Kilifi County Hospital in Kenya over a five-year period. Children
were genotyped for SCA retrospectively and incidence rates calculated with reference to population
data. Overall, 576 of 18,873 (3.1%) admissions had SCA of whom the majority (399; 69.3%) were
previously undiagnosed. The incidence of all-cause hospital admission was 57.2/100 person years
of observation (PYO; 95%CI 52.6–62.1) in children with SCA and 3.7/100 PYO (95%CI 3.7–3.8) in
those without SCA (IRR 15.3; 95%CI 14.1–16.6). Rates were higher for the majority of syndromic
diagnoses at all ages beyond the neonatal period, being especially high for severe anemia (hemoglo-
bin <50 g/L; IRR 58.8; 95%CI 50.3–68.7), stroke (IRR 486; 95%CI 68.4–3,450), bacteremia (IRR
23.4; 95%CI 17.4–31.4), and for bone (IRR 607; 95%CI 284–1,300), and joint (IRR 80.9; 95%CI
18.1–362) infections. The use of an algorithm based on just five clinical features would have identi-
fied approximately half of all SCA cases among hospital-admitted children with a number needed to
test to identify each affected patient of only fourteen. Our study illustrates the clinical epidemiology
of SCA in a malaria-endemic environment without specific interventions. The targeted testing of
hospital-admitted children using the Kilifi Algorithm provides a pragmatic approach to early diagno-
sis in high-prevalence countries where newborn screening is unavailable.
1 | INTRODUCTION
Sickle cell anemia (SCA) is a major global public health concern of which
sub-Saharan Africa bears the greatest load. More than 3 out of 4 of all
those affected worldwide are born within the region—almost a quarter
of a million new births every year.1 The allele responsible, the bs muta-
tion in HBB, is the textbook example of a balanced polymorphism in
humans.2 The sickle mutation has been selected to high population fre-
quencies in many tropical regions because carriers (HbAS) are strongly
protected against death from P. falciparum malaria3; however,
homozygotes with SCA suffer chronic ill health and reduced survival1
and even today, without specific treatment most children born with
SCA in sub-Saharan Africa will die before their fifth birthday.4
Although the clinical epidemiology of SCA has been well described
in resource-rich regions, most notably through the Cooperative Study
of Sickle Cell Disease in the United States,5 few studies have been con-
ducted in sub-Saharan Africa.6 This is important because the natural
history of SCA is likely to differ in the African context for reasons that
include the heavy burden of malaria and other infections, more limited
access to medical care and high rates of undernutrition.7,8
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In this study, our aim was to document the common complications
of SCA in a typical African hospital. Specifically, we wished to investi-
gate the current and future burdens placed by SCA on African health
facilities and the potential utility of targeted screening among specific
subgroups of hospital-admitted children as an alternative to newborn
screening in the community.
2 | METHODS
2.1 | Study population
The study was conducted on the pediatric wards of Kilifi County Hos-
pital on the Coast of Kenya. This serves as the first referral hospital for
Kilifi County where the common causes of admission are similar to
those in many hospitals in sub-Saharan Africa.9 In 2000, the Kilifi
Health and Demographic Surveillance System was established in a
defined area of 891 km2 surrounding Kilifi County Hospital, which
includes a population of around 100,000 children younger than 14
years.10 Approximately 80% of children who are admitted to Kilifi
County Hospital reside within the Kilifi Health and Demographic Sur-
veillance System study area.10 At the time of sampling, and even to
date, there was no routine screening for SCA anywhere in Kenya nor
any specific nationally based guidelines regarding management.
Hydroxyurea treatment, now commonly used in high-income countries,
was not available.
2.2 | Study participants
A system of routine clinical surveillance has been operating at Kilifi
County Hospital since 1989 through which trained clinicians assess all
children at both admission and discharge, and record standard data on
a computerized proforma.10 A range of laboratory tests are conducted
on all admitted children which include a full hemogram, a malaria blood
film, and a blood culture.11 Admission samples from this surveillance
system have been archived at 2808C since 2000. This study included
all children younger than 14 years who were residents of the Kilifi
Health and Demographic Surveillance System study area and who
were admitted to Kilifi County Hospital between January 2000 and
December 2004. We chose this study interval because during this
period malaria was the commonest cause of pediatric admission9 and
the incidence of uncomplicated malaria in the surrounding community
was between one and three episodes/child/year,9 allowing us to
address the important question of the relative contribution of malaria
to ill health in children with SCA in Africa. Furthermore, this predated
the introduction of routine immunization against pneumococcal infec-
tions and of the wide-spread diagnosis and provision of care for chil-
dren with SCA. As such, the study is broadly representative of the
natural history of SCA in the absence of specific interventions. All cases
were classified according to their SCA status (SCA - HbSS; non-SCA -
HbAA or HbAS), determined through the genotyping of archived
admission samples during 2015 and 2016, and also on the basis of a
range of clinical and laboratory features (Table 2). Finally, through care-
ful inspection of their clinical notes, confirmed cases of SCA were
further classified according to a number of additional features that
were specific to children with SCA but that are not ordinarily captured
by our clinical surveillance database. Such complications included pain,
hand-foot syndrome and priapism, as defined in Table 5. Incidence
rates were computed through use of the mid-study population of the
Kilifi Health and Demographic Surveillance System study area10 strati-
fied by the age-specific prevalence of SCA. As described in detail previ-
ously, we determined the latter by typing for SCA children who we
recruited by random sampling throughout the Kilifi Health and Demo-
graphic Surveillance System study area into studies undertaken
between 1998 and 2005.12 Informed consent for inclusion in the hos-
pital surveillance study was obtained from all participants or their
parents while permission to test admission samples retrospectively for
SCA was provided by the Kenya Medical Research Institute/National
Ethical Review Committee. We attempted to trace all SCA-children
identified through this study to offer them counseling and specialist
care.
2.3 | Laboratory procedures
Admission hemograms, blood film examinations for malaria, and blood
cultures were performed as previously described.9,11 We tested cases
for SCA by PCR13 in 2016, more than 10 years after the period of sam-
ple collection, using DNA extracted by proprietary methods [ABI
PRISM (Applied BioSystems, CA) or Qiagen DNA Blood Mini Kit (Qia-
gen, West Sussex, UK)] from archived samples of whole blood collected
at the time of their hospital admission. As a consequence, these geno-
typing results were not available to affected children or to the admit-
ting clinicians during the data collection period. Samples for our
denominator estimates—the random population samples described
above—were tested by alkaline electrophoresis of fresh blood samples
collected into EDTA on cellulose acetate membranes using proprietary
methods (Helena, Sunderland, Tyne & Wear, UK).
2.4 | Statistical analysis
All analyses were conducted using Stata v14.2 (Stata Corp, Timberlake).
Continuous data were compared using parametric or nonparametric
tests as appropriate, while proportions were compared using the v2
test. Sensitivities and positive predictive values (PPVs) were computed
using the “diagt” command. We calculated the incidence of syndrome-
specific admission to Kilifi County Hospital in SCA and non-SCA chil-
dren from the mid-study population of the Kilifi Health and Demo-
graphic Surveillance System area and the age-specific prevalence of
SCA among controls.12
3 | RESULTS
A total of 20,574 children <14 years were admitted to the wards of
Kilifi County Hospital from within the Kilifi Health and Demographic
Surveillance System study area during the study period, of whom
18,873 (92%) were genotyped successfully and included in this analysis
(Supporting Information Figure). The demographic, anthropometric and
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hematological characteristics of children at the point of admission,
stratified by SCA status, are summarized in Table 1. We found no evi-
dence for a prior diagnosis in 399 of 576 (69.3%) SCA admissions.
Overall, children with SCA accounted for 3.1% of all admissions and
were typically older, less-well nourished, and differed from children
without SCA across a range of hematological parameters (Table 1). Fur-
thermore, among those with SCA, previously diagnosed patients were
older (50.9 vs. 22.3 months) and better nourished [height-for-age Z
score (HAZ) 21.05 vs. 21.45; P5 .003] than undiagnosed children
(Supporting Information Table S1). Compared with non-SCA admissions
(7610/18292; 42%), those with SCA were less likely to be positive for
P. falciparum malaria parasites (98/576; 17%; P< .0005; Table 2) and
parasite densities were significantly lower in those who were infected
(Table 1). While mortality among parasite-positive patients with SCA
(4/98; 4.1%) was higher than that in those without SCA (199/7610;
2.6%), this did not reach statistical significance (v250.81).
The clinical phenotypes and outcome of hospital admission,
together with data on the potential value of such phenotypes as pre-
dictors of SCA, are summarized in Table 2. While children with SCA
were over-represented among some clinically defined subgroups,
including those with clinically detectable jaundice, severe anemia
(Hb<50 g/L) and a range of specific bacterial infections, they were
under-represented among both children admitted with malaria and
those admitted during the neonatal period. Although some syndromes,
including jaundice, severe anemia and stroke, were associated with
PPVs of >10%, the same diagnoses did not generally provide a sensi-
tive basis for the targeted screening of hospital-admitted children. We
therefore investigated whether a multi-disease approach to screening
might provide a more efficient strategy. To answer this question we
developed an algorithm based on a range of clinical syndromes ordered
hierarchically on the basis of their sensitivity and PPV profiles. Given
that, in general, it is unnecessary to screen children more than once,
we limited this analysis to index admissions for SCA-patients admitted
more than once. We re-classified each syndrome in this hierarchy to be
mutually exclusive of the preceding syndrome, allowing us to estimate
the cumulative PPVs and numbers needed to test (NNT) to identify
each affected case (Table 3). From this analysis we conclude that by
testing all children presenting with just one of five syndromes—stroke,
severe anemia, jaundice, septic arthritis and cellulitis, pyomyositis, or
abscess we would have identified 47% of all those with SCA by testing
only 14% of all those admitted: a NNT to identify each affected child
of 14. Testing all admitted children would have been more sensitive
(100%) but at the expense of a NNT of 47.
The incidence rate ratios (IRRs) for admission with various syn-
dromes in SCA compared to non-SCA children are shown in Table 4
while the equivalent incidence rates are summarized in Supporting
Information Table S2. The overall incidence rates for all-cause admis-
sion were 57.2/100 person years of observation (PYO) (95% CI 52.6–
62.1) and 3.7/100 PYO (95% CI 3.7–3.8) in SCA and non-SCA children
respectively (IRR 15.3; 95% CI 14.1–16.6). However, in contrast to
non-SCA children, the incidence rates for admission with a range of
syndromes rose strongly with age among those with SCA and, as a
result, we present these data stratified by age category (Table 4 and
Supporting Information Table S2). Incidence rates were significantly
higher among SCA children for the majority of diagnoses at all ages
beyond the neonatal period, but were especially high for stroke (IRR
486; 95% CI 68.4–3450), bacteremia (IRR 23.4; 95% CI 17.4–31.4) and
for bone (IRR 607; 95% CI 284–1300) and joint (IRR 80.9; 95% CI
18.1–362) infections (Table 4). The raised IRRs for many diagnoses
were most marked among undiagnosed children (Supporting Informa-
tion Table S3). The most common bacteremic infections were due to
non-typhi Salmonella species, Haemophilus influenzae and Streptococcus
pneumoniae (Table 2). Severe anemia complicated 31.3% of all SCA
admissions while 28.7% received a blood transfusion. This was
reflected in an overall IRR for severe anemia of 58.8 (95% CI 50.3–
68.7)/100 PYO, and rose with age from 6.7 (95% CI 4.6–9.7)/100 PYO
in the age group 0–11 months to 165 (95% CI 135–201)/100 PYO in
children over 2 years of age. Although malaria parasitemia was more
TABLE 1 Clinical and laboratory characteristics of hospital-admitted patients, stratified by SCA status
Non-SCA SCA
18,297 (96.9%) 576 (3.1%)
Characteristic Mean 95% CI Mean 95% CI P
Agea (months) 14.0 13.7–14.3 28.8 26.1–31.9 <.0005
WAZ 21.68 21.70, 21.66 21.82 21.93, 21.71 .056
HAZ 21.33 21.35, 21.30 21.33 21.45, 21.20 .997
Parasite density (parasites/lL) 27,101 25,644–28,674 3,468 2,238–5,376 <.0005
Hemoglobin (g/L) 92.0 91.6–92.5 65.6 63.1–68.0 <.0005
RCCa (x1012/L) 3.75 3.73–3.77 2.33 2.23–2.43 <.0005
MCV (fL) 74.0 73.8–74.2 81.5 80.5–82.5 <.0005
WBCa (3109/L) 12.2 12.1–12.3 22.9 21.7–24.0 <.0005
Plateletsa (3106/L) 236 232–239 293 276–310 <.0005
Abbreviations: WAZ, weight-for-age Z-score; HAZ, height-for-age Z-score; RCC, red cell count; MCV, mean cell volume; WBC, white blood count.
P-values in comparison to non-SCA children were estimated by use of Student’s t-tests.
aGeometric mean.
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common among SCA children with than without anemia (24.2% vs.
14.1%, respectively; P5 .003), blood films were negative in the major-
ity of anemic cases. Finally, the incidence rates for a range of specific
complications of SCA are summarized in Table 5. While the incidence
of admission with pain was 12.7 episodes/100 PYO overall, this was
strongly age dependent and was highest (27.2 episodes/100 PYO)
among children more than 2 years old. No episodes of priapism were
reported during the period of study.
4 | DISCUSSION
An estimated 312,000 babies are born with SCA worldwide every
year.7 Approximately 75% of these births occur in sub-Saharan Africa7
where historically, the disease has been widely neglected.14 As a conse-
quence, 50–90% of those affected die, usually undiagnosed, during
early childhood.4 These figures are reflected in estimates from the
Word Health Organization (WHO) which suggest that in many parts of
the continent SCA may account for between 5 and 16% of all deaths
among children <5 years old.15 Despite these figures, few reports have
described the epidemiology of SCA within the region and those studies
that have been conducted have largely focused on symptomatic chil-
dren whose disease may well have been modified by supportive
interventions.16
Our study used a retrospective design in which we exploited data
and samples collected through routine surveillance at Kilifi County
Hospital to study the epidemiology of SCA in an African population
under high malaria exposure. To a large extent, this retrospective
approach overcomes the potential biases that may be associated with a
known diagnosis or by the widespread provision of supportive
interventions.
The overall incidence of admission to hospital among children
with SCA 0–13 years was 57.2 (95% CI 52.6–62.1)/100 PYO.
TABLE 2 The clinical phenotypes of hospital-admitted patients, stratified by SCA status
Syndrome
Non-SCA
N5 18,297
SCA
N5576 Sensitivity 95% CI PPV 95% CI
Clinical syndromes
Neonatal conditions 1,839 (10.1) 19 (3.3) 3.3 2.0–5.1 1.0 0.6–1.6
Malaria 5,561 (30.4) 47 (8.2) 8.2 6.1–10.7 0.8 0.6–1.1
Severe malaria 861 (4.7) 11 (1.9) 1.9 1.0–3.4 1.3 0.6–2.3
Severe pneumonia 500 (2.7) 17 (3.0) 3.0 1.7–4.7 3.3 1.9–5.2
Very severe pneumonia 10,836 (59.2) 315 (54.7) 54.7 50.5–58.8 2.8 2.5–3.2
Meningitis/encephalitis 3,076 (16.8) 49 (8.5) 8.5 6.4–12.0 1.6 1.2–2.1
Severe malnutrition 1,595 (8.7) 47 (8.2) 8.2 6.1–10.7 2.9 2.1–3.8
Gastroenteritis 3,417 (18.7) 50 (8.7) 8.7 6.5–11.3 1.4 1.1–1.9
Jaundice 682 (3.7) 107 (18.6) 18.6 15.5–22.0 13.6 11.3–16.2
Cellulitis/pyomyocitis/abcess 333 (1.8) 17 (3.0) 3.0 1.7–4.7 4.9 2.9–7.7
Septic arthritisa 12 (0.1) 2 (0.4) 0.4 0–1.3 14.3 1.8–42.8
Osteomyelitisb 12 (0.1) 15 (2.6) 2.6 1.5–4.3 55.6 35.3–74.5
Stroke 2 (0.01) 2 (0.4) 0.4 0–1.3 50.0 6.8–93.2
Other 1,687 (9.2) 120 (20.8) N/A N/A N/A N/A
Laboratory based syndromes
Neonatal bacteremia 160 (0.9) 2 (0.4) 0.4 0–1.3 1.2 0.2–4.4
Bacteremiac 956 (5.2) 46 (7.2) 7.2 5.9–10.5 4.6 3.4–6.1
Malaria blood film positive 7,610 (41.6) 98 (17.0) 17.0 14.0–20.3 1.3 1.0–1.6
Severe anemia 1,470 (8.2) 178 (31.3) 31.3 27.5–35.3 10.8 9.3–12.4
Outcome
Blood transfusion 1,623 (8.9) 165 (28.7) N/A N/A N/A N/A
Death 1,089 (5.9) 32 (5.6) N/A N/A N/A N/A
Figures in parentheses are column percentages. Clinical phenotypes were defined as follows: “neonatal conditions”—admission to hospital within the
first 28 days of life; “malaria”—a fever in the presence of P. falciparum parasitemia at any density in children <1 year old or at a density of >2500 para-
sites/lL in older children; “severe malaria”—malaria in association with the specific complications of prostration, coma, respiratory distress, or a Hb of
<50 g/L; “severe” and “very severe pneumonia”—defined as previously described31; meningitis/encephalitis—the clinical detection of “neck stiffness,”
prostration or coma (defined as a Blantyre Coma Score of <5), or a bulging fontanel; “severe malnutrition”—a mid-upper-arm circumference of 7.5 cm
in children <6 months or of 11.5 in children 6 months of age; “gastroenteritis”—diarrhoea (3 or more loose watery stools/day) with or without vom-
iting (3 or more episodes/day); “jaundice”—the clinical recognition of jaundice by the admitting clinician; “osteomyelitis”—bacterial bone infection diag-
nosed either clinically or with supportive radiological or microbiological evidence; “cellulitis/pyomyositis/abscess”—diagnosed clinically with or without
supportive microbiological evidence; “septic arthritis” diagnosed clinically with or without supportive microbiological evidence; and “stroke”—sudden
onset of unilateral weakness persisting for more than seven days and for which other diagnoses had been excluded. Some children contribute data to
more than one row.
aBlood cultures were positive for nontyphoidal Salmonella spp in one SCA case.
bBlood cultures were positive for nontyphoidal Salmonella spp in two SCA cases.
cPositive cultures among children with SCD were Acinetobacter spp (3; 7%), Enterobacter cloacae (1; 2%), Escherichia coli (2; 4%), Haemophilus influenzae
(7; 15%), Klebsiella pneumoniae (1; 2%), non-typhoidal Salmonella spp (8; 17%), Salmonella typhi (1; 2%), Staphylococcus aureus (2; 4%), Streptococcus
pneumoniae (19; 41%) and other Streptococcal spp (2%).
Sensitivities and PPVs were computed using the “diagt” command in Stata v14.2.
N/A: not applicable.
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However, this was strongly age-dependent and rose from 29.7 (95%
CI 24.7–35.4)/100 PYO in children 0–11 months to 78.6 (95% CI
70.6–87.2)/100 PYO in the age-group 3–13 years. For a number of
reasons, we suggest that these figures reflect a significant underesti-
mate of the total impact of SCA within our study population. First,
while Kilifi County Hospital is the main provider of medical care
TABLE 3 The potential utility of targeted approaches to SCA screening among patients admitted to the pediatric ward at Kilifi County
Hospital
Syndrome
Non-SCA
N518,297
SCA
N5 399
Cumulative
Sensitivity (%) PPV (%) NNT
Cumulative
NNT
Proportion of
all admissions (%)
Stroke 2 (0.01) 1 (0.25) 0.25 33.3 3 3 0.02
Severe anemia 1,470 (8.03) 130 (32.6) 32.8 8.1 12 12 8.6
Jaundice 634 (3.47) 38 (9.52) 42.4 5.7 18 13 12.2
Septic arthritis 12 (0.07) 2 (0.50) 42.9 14.3 7 13 12.2
Cellulitis/pyomyositis/abcess 323 (1.77) 14 (3.51) 46.4 4.2 24 14 14.0
Bacteremia 780 (4.26) 21 (5.26) 51.6 2.6 38 17 18.3
Osteomyelitis 8 (0.04) 2 (0.50) 52.1 20.0 5 17 18.4
Very severe pneumonia 8,999 (49.2) 114 (28.6) 80.7 1.3 80 39 67.1
Severe pneumonia 397 (2.17) 7 (1.75) 82.5 1.7 58 39 69.3
Severe malnutrition 440 (2.40) 7 (1.75) 84.2 1.6 64 40 71.7
Other 5232 (28.6) 63 (15.8) 100.0 1.2 84 47 100.0
Abbreviations: PPV, positive predictive value; NNT, number needed to test.
Values were computed from the data summarized in Table 2 using the “diagt” command in Stata v14.2. Syndromes were defined as described in Table 2.
TABLE 4 IRRs for admission to hospital with specific clinical diagnoses in SCA versus non-SCA children
0–13 Years 0–11 Months 12–23 Months 2–13 Years
Diagnosis IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI
Clinical syndromes
All cause hospital admission 15.3 14.1–16.6 1.7 1.4–2.0 6.8 5.5–8.2 45.4 40.8–50.5
Neonatal conditions 0.7 0.4–1.1 0.7 0.4–1.1 N/A N/A N/A N/A
Malaria 4.10 3.1–5.5 0.8 0.5–1.4 1.4 0.7–2.9 9.4 6.5–13.6
Severe malaria 6.2 3.4–11.2 3.1 1.3–7.6 5.1 1.9–13.6 3.8 0.9–15.2
Severe pneumonia 16.5 10.2–26.8 2.5 1.3–5.1 17.8 7.8–40.6 28.2 9.0–89.0
Very severe pneumonia 14.1 12.6–15.8 1.8 1.4–2.2 6.3 4.8–8.2 42.6 36.6–49.5
Meningitis/encephalitis 7.7 5.8–10.3 1.3 0.9–1.8 7.2 3.4–15.3 18.8 11.3–31.4
Severe malnutrition 14.3 10.7–19.1 2.20 1.4–3.5 9.5 5.8–15.6 35.8 20.6–62.4
Gastroenteritis 7.1 5.4–9.4 1.6 1.1–2.4 3.3 1.9–5.8 12.7 6.8–23.7
Jaundice 76.2 62.1–93.4 2.2 1.2–4.0 116 59.4–228 467.4 359–608
Cellulitis/pyomyositis/abcess 24.8 15.2–40.4 3.5 1.3–9.4 14.6 5.4–39.9 57.0 29.1–111
Septic arthritis 80.9 18.1–362 32.2 3.4–310.1 N/A N/A 101.4 12.9–800
Osteomyelitis 607 284–1300 96.8 6.1–1550 844 87.8–8120 1003 426–2360
Stroke 486 68–3450 N/A N/A N/A N/A 456 41.4–5032
Other 35 29–42 2.0 0.8–4.7 9.7 5.6–16.8 87.7 71.60–107.50
Laboratory features and outcomes
Neonatal bacteremia 0.8 0.2–3.3 0.8 0.2–3.3 N/A N/A N/A N/A
Bacteremia 23.4 17.4–31.4 3.4 2.0–5.5 12.5 6.2–25.4 63.7 41.4–98.2
Malaria blood film positive 6.3 5.1–7.6 1.0 0.7–1.7 2.8 1.8–4.4 13.8 10.7–17.7
Severe anemia 58.8 50.3–68.7 6.7 4.6–9.7 22.5 15.7–32.3 165 135–201
Transfused 49.4 42.1–57.9 3.8 2.5–5.7 20.3 13.8–29.7 165 135–201
Died 14.3 10.0–20.3 2.0 1.2–3.5 12.1 5.3–27.3 37.3 21.4–65.0
The IRRs for each syndrome and age group were estimated using a series of Poisson regression models. In each syndrome-specific model the count of
that syndrome was the outcome variable and the indicator for SCA was the explanatory variable. The exposure time in each model was PYO estimated
as described in the methods. The mid-study population of the Kilifi Health and Demographic Surveillance System study area was 615 for children 0–28
days, 8,173 for children aged 0–11 months, 7,964 for those aged 12–23 months, and 81,857 for 2–13 year olds; the proportions with SCA in these
age groups were 1.52% (95% CI 0.19–2.85), 1.02% CI 0.44–2.01), 0.35% (0.35–1.96), and 0.11% (0.03–0.28), respectively. In each age group, the num-
ber of PYO was calculated from the product of the mid-study population, the prevalence of SCA and the duration of the study in years. The figures for
each group were as follows non-SCA: 0–28 days 36,341; 0–11 months 40,447; 12–23 months 39,679; 2–13 years 408,837; 0–13 years 488,963; SCA
0–28 days 559; 0–11 months 418; 12–23 months 141; 3–13 years 448; 0–13 years 1007.
N/A, not applicable.
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within the study area, it is likely that some children will have sought
care in hospitals beyond the study borders. Second, it is likely that
the costs associated with medical consultation and hospital admission
will have deterred some parents from seeking care. As a result, our
study may not have captured all significant events among resident
children with SCA.
In contrast to observations made in resource-rich countries
through studies like the US cooperative study for sickle cell disease,5
where hand-foot syndrome was a common presenting feature of SCA,
its incidence was low in the current study. While this might simply
reflect methodological issues, it could also result from a true difference
in the clinical phenotype of SCA within our study population, poten-
tially explained by genetic or environmental factors. Conversely, severe
anemia was significantly more common in our study than in reports
from the north. For example, while the overall incidence of anemia in
the cooperative study was <5/100 PYO,5 in our study it was 17.7/100
PYO and reached 26.1/100 PYO among children >2 years old. More
than 30% of SCA admissions were severely anemic and 28.7% received
one or more transfusions—almost one out of every 10 pediatric trans-
fusions administered at Kilifi County Hospital during the study period.
While the design of our study does not allow us to determine the pre-
cise etiology of these anemic episodes, the most likely explanations for
this geographic discrepancy relate to malaria or nutrition. Although chil-
dren with SCA are thought to be partially resistant to malaria infec-
tion,17 a theory supported by the lower prevalence and density of P.
falciparum infections seen in this study, the disease can take a particu-
larly fulminant course when patients are infected.18 While direct evi-
dence of malaria infection was only seen in a quarter of these children,
this does not exclude a wider role for malaria through, for example,
previous, recurrent or pre-treated infections. Regardless of the cause, it
is clear that in sub-Saharan Africa, severe anemia places a heavy bur-
den both on children with SCA, their families and on medical services
constrained by limited resources. A particular concern relates to blood
safety. Even in well-resourced areas, transfusions are associated with
risks and are not administered without careful consideration.19 Specific
factors like the frequent use of non-leuko-depleted whole blood, lim-
ited cross-matching procedures and suboptimal storage conditions
magnify these risks in sub-Saharan Africa,20 and it is for such reasons
that the WHO recommends restricting transfusions to the children in
greatest need.20 For all these reasons, early life screening could have a
marked impact on anemia through the targeted prevention of malaria
and by helping clinicians to make more informed decisions about when
and how to transfuse affected children.21
In common with other regions,5,22–24 and as described in detail
previously,12 bacterial infections were an important reason for hos-
pital admission among children with SCA in our study. Similarly,
despite design differences, both our rate and age-pattern of painful
crises were broadly similar to those seen in the Cooperative Study.5
Conversely, the incidence of stroke, a major complication of SCA in
resource-rich regions,1,5 was significantly lower, most likely reflect-
ing the low rates of survive to the age at which the incidence of
stroke begins to rise. Of particular note, the raised incidence of
many complications, including malaria, anemia, bacterial infections,
and in-hospital death, was most pronounced among undiagnosed
children. This may reflect improved parental education concerning
SCA and adherence to antimalarial and antibacterial prophylaxis by
children once diagnosed.
While newborn screening would be the best way to identify chil-
dren with SCA and direct them towards treatment as early in life as
possible, this is challenging in sub-Saharan Africa14 and there are few
locations within the region where such programs have been established
successfully.25–27 A major rationale for conducting this study was
therefore to investigate the potential utility of screening among specific
sub-groups of hospital-admitted children as a pragmatic alternative.
This approach is widely practiced for HIV where, for example, the
WHO recommend provider-initiated testing and counselling for all chil-
dren presenting to health facilities in low-income countries.28 Although
individually none of the clinical syndromes investigated were suffi-
ciently specific to make them especially useful, a number of factors
were associated with PPVs of >10%. These included clinical jaundice,
severe anemia, bone and joint infections and stroke. We have shown
that through the use of a clinical algorithm based on just 5 diagnoses,
we would have identified almost half of all SCA-children within the
patient population with a NNT of only 14. It is likely that more children
could have been identified with a lower NNT had we included other
characteristic complications such as hand-foot syndrome and unex-
plained pain in our algorithm. Although our study design meant that
we lacked the control data for such syndromes that would have
enabled us to test this definitively, in practice, we suggest that by
including in our algorithm children admitted with such characteristic
features of SCA would improve its performance at limited additional
cost. While blood film microscopy or rapid methods such as the
TABLE 5 The incidence of hospital admission with a range of SCA-specific complications for which data were not routinely captured through
our ward surveillance system
0–13 years 0–11 months 12–23 months 2–13 years
Complication n Incidence (95% CI) n Incidence (95% CI) n Incidence (95% CI) n Incidence (95% CI)
Pain 128 12.7 (10.6,15.1) 0 – 6 4.3 (1.6,9.3) 122 27.2 (22.6,32.5)
Hand-foot syndrome 15 1.5 (0.8,2.4) 4 1.0 (0.3,2.5) 4 2.8 (0.8,7.3) 7 1.6 (0.6,3.2)
Arthralgia 34 3.4 (2.3,4.7) 0 – 1 0.7 (0,4.0) 33 7.4 (5.1,10.3)
PYO were derived as described in Table 4. Specific features were determined through physical inspection of the clinical notes of all children with SCA.
Pain, any mention of un-explained pain; hand-foot syndrome, painful swelling of hands or feet; arthralgia, specific mention of pain in any joint. Some
patients manifest more than one complication. No episodes of priapism were identified during the course of this study. Some patients manifest more
than one complication.
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sodium metabisulphite sickling test represent potential approaches to
screening, they both require a basic laboratory staffed by a trained
technician and lack both specificity and sensitivity with regard to dif-
ferentiating trait from disease. However, the recent development of
simple and accurate point-of-care testing devices for SCA29 now
makes opportunistic testing at the bed-side much more practical. We
recommend that where newborn screening is not available, hospitals
in Africa should use the Kilifi Algorithm coupled to point-of-care test-
ing as a pragmatic alternative.
In summary, we have described the clinical epidemiology of SCA
within a malaria-exposed population in Africa. We highlight important
differences in comparison to descriptions from resource-rich regions
including a significantly higher incidence of severe anemia. We show
that targeted screening of hospital-admitted children based on a small
number of easily recognized syndromes provides a practical and effi-
cient way to identify a high proportion of affected children and intro-
duce them to care. If the world continues to ignore the problem of
SCA, the disease will continue to result in high child-mortality and
threaten the ability of many countries in sub-Saharan Africa to meet
their Sustainable Development Goals.30 The need is urgent for a
renewed and increased focus on SCA by both African governments
and the international community.
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